Sandra Wymann

Company: CSL Behring

Job title: Associate Director

Seminars:

CSL040: A Novel Complement Inhibitor Across all 3 Pathways 9:30 am

Discussing the recombinant glycoprotein that inhibits the classical, lectin and alternative pathways Treating acute indications involving complement-mediated tissue damage and inflammation Strategies for initial PK/PD and toxicology studies for complement inhibitorsRead more

day: Conference Day One

Navigating Clinical Trials: Overcoming Challenges in Complement Drug Development for Breakthrough Success 3:30 pm

Delving into the strategic expansion of indications for complement inhibitors beyond their initial targets. Explore the processes and considerations involved in identifying new therapeutic areas, conducting late-stage translational research, and managing clinical development to bring these therapies from rare disease to indications like dry AMD. Design trials that include both traditional and innovative endpoints, such…Read more

day: Pre-Conference Workshop Day